Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials (Q30673291)

26 June 2017

Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials (English)

1 reference

26 June 2017

phase III clinical trial

0 references

1 reference

1 reference

C Twelves

1

1 reference

PubMed ID

11841931

26 June 2017

Xeloda Colorectal Cancer Group

series ordinal

2

1 reference

26 June 2017

1 February 2002

1 reference

European Journal of Cancer

26 June 2017

1 reference

26 June 2017

38 Suppl 2

1 reference

26 June 2017

15-20

1 reference

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

26 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900415-4

7 January 2021

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900415-4

7 January 2021

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900415-4

7 January 2021

Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900415-4

7 January 2021

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900415-4

7 January 2021

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900415-4

7 January 2021

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900415-4

7 January 2021

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900415-4

7 January 2021

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900415-4

7 January 2021

Future treatment options with capecitabine in solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900415-4

7 January 2021

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900415-4

7 January 2021

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900415-4

7 January 2021

10.1016/S0959-8049(01)00415-4

Identifiers

DOI

1 reference

26 June 2017

1 reference

PubMed ID

11841931